ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism

Permanent link
https://hdl.handle.net/10037/22769
DOI
https://doi.org/10.1182/bloodadvances.2020003135
Thumbnail
View/Open
article.pdf (920.2Kb)
Published version (PDF)
Date
2021-01-07
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Edvardsen, Magnus; Hindberg, Kristian; Hansen, Ellen-Sofie; Morelli, Vania Maris; Ueland, Thor; Aukrust, Pål; Brækkan, Sigrid Kufaas; Holtet Evensen, Line; Hansen, John-Bjarne
Abstract
Several case-control studies have reported elevated plasma von Willebrand factor (VWF) levels in patients with venous thromboembolism (VTE) compared with controls. However, because few studies have investigated the association in a prospective design, it is unclear whether elevated plasma VWF is a risk factor or a consequence of the VTE event. Therefore, we aimed to investigate the prospective association between plasma VWF levels and risk of VTE, as well as to perform subgroup analyses of deep vein thrombosis (DVT) and pulmonary embolism. We established a population-based nested case-control study of 414 VTE cases and 843 age- and sex-matched controls based on the Tromsø study cohort (1994-2007). Blood samples were collected at cohort baseline (1994-1995). Odds ratios (ORs) with 95% confidence intervals (CIs) for VTE were estimated across quartiles of VWF levels. We found that the risk of VTE increased linearly across quartiles of VWF levels (P for trend = .023). Participants with VWF in the highest quartile had an OR of 1.45 (95% CI, 1.03-2.03) for VTE compared with those in the lowest quartile. The association was strongest for unprovoked VTE (OR, 2.74; 95% CI, 1.66-4.54) and unprovoked DVT in particular (OR, 6.73; 95% CI, 3.07-14.76). Further adjustment for body mass index, C-reactive protein, hypertension, estrogen use, and smoking had a modest effect on the risk estimates. To conclude, we found a dose-dependent relationship between plasma VWF levels and future risk of incident VTE, and unprovoked events in particular. Our findings suggest that VWF may represent a promising biomarker for future risk of incident VTE.
Is part of
Edvardsen, M.S. (2024). Plasma von Willebrand factor and risk of future venous thromboembolism. (Doctoral thesis). https://hdl.handle.net/10037/33570.
Publisher
American Society of Hematology
Citation
Edvardsen, Hindberg, Hansen, Morelli, Ueland, Aukrust, Brækkan, Holtet Evensen, Hansen. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Advances. 2021;5(1):224-232
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (klinisk medisin) [1974]
Copyright 2021 The Author(s)

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)